<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAN</journal-id>
<journal-id journal-id-type="hwp">spcan</journal-id>
<journal-title>ICAN: Infant, Child, &amp; Adolescent Nutrition</journal-title>
<issn pub-type="ppub">1941-4064</issn>
<issn pub-type="epub">1941-4072</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1941406412439232</article-id>
<article-id pub-id-type="publisher-id">10.1177_1941406412439232</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Feature Articles</subject>
<subj-group subj-group-type="heading">
<subject>Evidence-Based Practice Reports</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Nutritional Management of the Child With Crohn’s Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Rosen</surname><given-names>Daphna</given-names></name>
<degrees>RN, PNP</degrees>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>John</surname><given-names>Rita Marie</given-names></name>
<degrees>DNP, EdD, CPNP</degrees>
</contrib>
<aff id="aff1-1941406412439232">Columbia University School of Nursing, New York, NY</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1941406412439232">Daphna Rosen, Columbia University School of Nursing; e-mail: <email xlink:type="simple">Dr2521@columbia.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>4</volume>
<issue>2</issue>
<fpage>111</fpage>
<lpage>121</lpage>
<permissions>
<copyright-statement>© 2012 The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Nutritional management of Crohn’s Disease (CD) is essential when working with the pediatric population. Treatment needs to target not only symptoms of the disease but also the associated growth failure and nutritional deficiencies. The principle nutritional therapy is the use of enteral nutrition, which has been shown to be safe and effective in both the induction of remission and maintenance in pediatric CD. Additional nutritional supplementation, including omega-3 fatty acids, probiotics, and glutamine, have been researched, but have not been proven effective. This article will address the role of nutritional therapy and management in pediatric CD, the different nutritional management options, the role of nutritional therapy in the induction and maintenance of remission, and recommendations for health care professionals who care for children with CD.</p>
</abstract>
<kwd-group>
<kwd>Crohn’s disease</kwd>
<kwd>pediatric</kwd>
<kwd>nutrition</kwd>
<kwd>management</kwd>
<kwd>health care professional</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>
<disp-quote>
<p>The immediate goals of nutritional management are to induce and maintain remission to ultimately improve overall growth, development, and nutritional status.</p>
</disp-quote>
</p>
<p>JR is a 14-year-old boy with newly diagnosed Crohn’s Disease (CD). He presents with abdominal pain, weight loss, diarrhea, impaired linear growth, and pubertal impairment. What important nutritional deficits should the health care professional be aware of and evaluate? What are the different nutritional treatment and management options available for this patient? Nutritional deficits leading to growth and developmental impairments are hallmarks of pediatric CD. Nutritional management, therefore, needs to be at the forefront in the treatment of CD. This article will address common nutritional problems; the importance, benefits, and outcomes of nutritional therapy in both the induction and maintenance of disease remission; and recommendations for health care professionals in the nutritional management of CD.</p>
<sec id="section1-1941406412439232">
<title>Overview</title>
<p>CD is a cyclical disease, which involves chronic inflammation with periods of remission followed by relapse.<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup> The disease, which can arise in any part of the intestine, is characterized by “skip lesions,” or granulomatous inflammations found commonly in the ileum, followed by the colon and small bowel, and gastroduodenal disease.<sup><xref ref-type="bibr" rid="bibr2-1941406412439232">2</xref>,<xref ref-type="bibr" rid="bibr3-1941406412439232">3</xref></sup> CD is commonly diagnosed in childhood and adolescence, with higher presentation occurring during the peripubertal years.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> CD comprises 25% of the newly diagnosed cases of inflammatory bowel disease.<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup> Height and weight are significantly reduced in CD: 22% to 24% of children with CD reported a low BMI.<sup><xref ref-type="bibr" rid="bibr5-1941406412439232">5</xref></sup></p>
</sec>
<sec id="section2-1941406412439232">
<title>Clinical Presentation</title>
<p>Clinical manifestations of CD can be abrupt, insidious, or poorly defined.<sup><xref ref-type="bibr" rid="bibr6-1941406412439232">6</xref></sup> Although the most common abdominal symptoms include weight loss or poor weight gain, abdominal pain, and diarrhea, extraintestinal manifestations are common.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> <xref ref-type="table" rid="table1-1941406412439232">Table 1</xref> summarizes the clinical presentation of CD. Two thirds of children with CD will present with weight loss, one third will have permanent growth impairment,<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> and many will have a reduction in lean body mass.<sup><xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref></sup></p>
<table-wrap id="table1-1941406412439232" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical Presentation</p>
</caption>
<graphic alt-version="no" alternate-form-of="table1-1941406412439232" position="float" xlink:href="10.1177_1941406412439232-table1.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Clinical Presentation</th>
<th align="center" colspan="1" rowspan="1">Associated Manifestations</th>
<th align="center" colspan="1" rowspan="1">Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">Poor weight gain/weight loss<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup></td>
<td colspan="1" rowspan="1">
<list id="list1-1941406412439232" list-type="bullet">
<list-item><p>Diarrhea<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup></p></list-item>
<list-item><p>Abdominal pain<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup></p></list-item>
<list-item><p>Malnutrition<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup>
</p></list-item>
</list></td>
<td colspan="1" rowspan="1">
<list id="list2-1941406412439232" list-type="bullet">
<list-item><p>Reduced caloric intake or caloric malabsorption<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup></p></list-item>
<list-item><p>Increased nutrient requirements<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup></p></list-item>
<list-item><p>Increased nutrient losses<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup></p></list-item>
<list-item><p>Drug–nutrient interactions<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup></p></list-item>
<list-item><p>Alteration of metabolism related to inflammation<sup><xref ref-type="bibr" rid="bibr51-1941406412439232">51</xref></sup></p></list-item>
</list>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Growth failure<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup></td>
<td colspan="1" rowspan="1">
<list id="list3-1941406412439232" list-type="bullet">
<list-item><p>Impaired linear growth<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
<list-item><p>Pubertal delay<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p></list-item>
<list-item><p>Malnutrition<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
</list></td>
<td colspan="1" rowspan="1">
<list id="list4-1941406412439232" list-type="bullet">
<list-item><p>Malnutrition<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
<list-item><p>Corticosteroid therapy<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
<list-item><p>Inflammatory mediators (IL-6, TNF-α)<sup><xref ref-type="bibr" rid="bibr51-1941406412439232">51</xref></sup></p></list-item>
</list></td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Nutritional deficiencies<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup></td>
<td colspan="1" rowspan="1"><list id="list5-1941406412439232" list-type="bullet">
<list-item><p>Malnutrition<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup></p></list-item>
<list-item><p>Decreased bone health<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p></list-item>
<list-item><p>Low bone mineral density<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p></list-item>
<list-item><p>Osteopenia<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup></p></list-item>
<list-item><p>Osteoporosis<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup></p></list-item>
</list></td>
<td colspan="1" rowspan="1">
<list id="list6-1941406412439232" list-type="bullet">
<list-item><p>Malnutrition<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref>,<xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p></list-item>
<list-item><p>Poor oral intake<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup></p></list-item>
<list-item><p>Corticosteroid therapy<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p></list-item>
<list-item><p>Inflammation related to disease activity<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p></list-item>
<list-item><p>Malabsorption<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup></p></list-item>
</list></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1941406412439232">
<p>Abbreviations: IL, interleukin; TNF, tumor necrosis factor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section3-1941406412439232">
<title>Growth Failure</title>
<p>Growth failure can be defined as delayed skeletal maturation and delayed pubertal onset.<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup> Impaired linear growth will be present in up to 50% of pediatric CD patients,<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> with a greater percentage of adolescent males versus females presenting with growth failure. Adolescent males are at greater risk for growth impairments because their pubertal growth spurt occurs later and extends for a longer duration than females.<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup> Growth failure results from inflammation of the intestine, treatment with steroids, changes in growth hormone secretion and insulin-like growth factor, and chronic undernutrition.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref>,<xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup> The insulin-like growth factor 1, total insulin growth factors, and IG-1 binding protein-3 (IGFBP-3) are lower in children with active inflammatory bowel disease.<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup> Chronic undernutrition is the main contributing factor in growth failure in CD.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> Osteopenia and osteoporosis develop as a result of malabsorption of calcium and vitamin D,<sup><xref ref-type="bibr" rid="bibr13-1941406412439232">13</xref></sup> decreased levels of vitamin K,<sup><xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref></sup> treatment with steroids, and chronic inflammation of the intestine.<sup><xref ref-type="bibr" rid="bibr2-1941406412439232">2</xref></sup></p>
<p>In addition to impaired linear growth, pubertal delay is also seen in children who fail to achieve remission or those who have frequent relapses.<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup> Close monitoring of pubertal advancement is extremely important in this patient population.</p>
</sec>
<sec id="section4-1941406412439232">
<title>Nutritional Deficiencies</title>
<p>Both macronutrient and micronutrient deficiencies related to malnutrition are common in children with active CD. During remission, macronutrient deficiencies are rarely seen in patients.<sup><xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref></sup> <xref ref-type="table" rid="table2-1941406412439232">Table 2</xref> lists common nutrient deficiencies. Pons et al<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup> evaluated the dietary intake of children with active CD, those in remission, and healthy children (<xref ref-type="table" rid="table3-1941406412439232">Table 3</xref> ). Researchers found that children with active CD have lower nutrient intake compared with that of children who were healthy or in remission.<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup> For example, lowered bone mineral density is common in children in CD<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref>,<xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup> as a result of lactose intolerance, decreased calcium intake,<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup> malnutrition, corticosteroid use, and inflammation related to disease activity.<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup> As the intestine heals, the absorption of micronutrients and macronutrients improves. Micronutrient deficiencies in iron, folate, and vitamin B12 are commonly observed. However, levels of vitamin A, vitamin E, β-carotene, magnesium, selenium, and zinc can also be reduced. Daily supplementation with calcium and vitamin D have been associated with an increase in bone mineral density,<sup><xref ref-type="bibr" rid="bibr13-1941406412439232">13</xref>,<xref ref-type="bibr" rid="bibr14-1941406412439232">14</xref></sup> and iron supplementation can improve the quality of life.<sup><xref ref-type="bibr" rid="bibr15-1941406412439232">15</xref></sup></p>
<table-wrap id="table2-1941406412439232" position="float">
<label>Table 2.</label>
<caption>
<p>Common Nutritional Deficiencies in Children With Active CD<sup>a</sup></p>
</caption>
<graphic alt-version="no" alternate-form-of="table2-1941406412439232" position="float" xlink:href="10.1177_1941406412439232-table2.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Micronutrient Deficiencies</th>
<th align="center" colspan="1" rowspan="1">Macronutrient Deficiencies</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Calcium</td>
<td colspan="1" rowspan="1">Carbohydrates</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Folate</td>
<td colspan="1" rowspan="1">Fats</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vitamin B12</td>
<td colspan="1" rowspan="1">Protein</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Zinc</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1">Selenium</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1">Iron</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1">Vitamin D</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1">Vitamin K</td>
<td colspan="1" rowspan="1"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1941406412439232">
<label>a</label>
<p>Adapted from Pons et al.<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1941406412439232" position="float">
<label>Table 3.</label>
<caption>
<p>Characteristics of Included Studies</p>
</caption>
<graphic alt-version="no" alternate-form-of="table3-1941406412439232" position="float" xlink:href="10.1177_1941406412439232-table3.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Author (Year Published)</th>
<th align="center" colspan="1" rowspan="1">Aim of Study</th>
<th align="center" colspan="1" rowspan="1">Participants</th>
<th align="center" colspan="1" rowspan="1">Methods</th>
<th align="center" colspan="1" rowspan="1">Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="5" rowspan="1">Nutritional deficiencies</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pons et al<sup><xref ref-type="bibr" rid="bibr1-1941406412439232">1</xref></sup> (2009)</td>
<td colspan="1" rowspan="1">To compare dietary intake and growth in children with CD and healthy children</td>
<td colspan="1" rowspan="1">63 Children (age range 10-16 years); 18 with active CD, 23 with CD in remission, 22 healthy controls</td>
<td colspan="1" rowspan="1">Nonrandomized controlled trial; food frequency questionnaire was used to assess dietary intake</td>
<td colspan="1" rowspan="1">Dietary intake is lower in children with active CD when compared with both healthy children and children in remission; carbohydrate intake was lower in those with active CD than in controls (<italic>P</italic> = .03); fat intake was lower in those with active CD than in controls (<italic>P</italic> = .06); protein intake was similar between all groups (<italic>P</italic> = .09)</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1">Induction of remission</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Berni Canani et al<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> (2006)</td>
<td colspan="1" rowspan="1">To evaluate the efficacy of different enteral formulas (elemental, semielemental, and polymeric) and corticosteroids in their achievement of maintenance of disease remission</td>
<td colspan="1" rowspan="1">47 Patients (age range 7-17 years); 37 received 8 weeks of nutritional therapy, and 10 received corticosteroids</td>
<td colspan="1" rowspan="1">Retrospective study with medical record review</td>
<td colspan="1" rowspan="1">Similar remission rates; 86.5% using nutritional therapy achieved remission versus 90% using corticosteroids (no statistical values reported). Nutritional therapy yielded greater mucosal healing and durations of remission (<italic>P</italic> &lt; .001)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Day et al<sup><xref ref-type="bibr" rid="bibr37-1941406412439232">37</xref></sup> (2006)</td>
<td colspan="1" rowspan="1">To show the success of enteral nutrition in induction of remission and maintenance in pediatric CD</td>
<td colspan="1" rowspan="1">27 Children (age range 3.8-16 years); 15 with newly diagnosed CD solely with exclusive enteral nutrition and 12 with long-standing disease managed with EEN and medications</td>
<td colspan="1" rowspan="1">Retrospective study with case record review</td>
<td colspan="1" rowspan="1">In all, 80% of newly diagnosed patients (<italic>P</italic> &lt; .0001) and 58% of patients with long-standing disease (<italic>P</italic> &lt; .0001) achieved remission. EEN is a safe and effective therapy</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Johnson et al<sup><xref ref-type="bibr" rid="bibr17-1941406412439232">17</xref></sup> (2006)</td>
<td colspan="1" rowspan="1">To compare partial enteral therapy and total enteral therapy in the treatment of active CD</td>
<td colspan="1" rowspan="1">50 Children (age range 3.8-16.0 years); 24 received total enteral nutrition, 26 received partial enteral nutrition</td>
<td colspan="1" rowspan="1">RCT</td>
<td colspan="1" rowspan="1">Total enteral nutrition had greater remission rates than partial enteral nutrition (<italic>P</italic> = .035); partial enteral nutrition did not have an impact on mucosal inflammation</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ludvigsson et al<sup><xref ref-type="bibr" rid="bibr18-1941406412439232">18</xref></sup> (2004)</td>
<td colspan="1" rowspan="1">To compare the efficacy and safety of elemental and polymeric diets as the primary therapy in active pediatric CD</td>
<td colspan="1" rowspan="1">33 Children (age range 10.9-17.6 years); 16 received Elemental 028 Extra formula, 17 received Nutrison Standard formula</td>
<td colspan="1" rowspan="1">Multicenter RCT</td>
<td colspan="1" rowspan="1">No significant difference between the remission rates of elemental and polymeric diets in 6 weeks (<italic>P</italic> = .438); greater weight gain with polymeric versus elemental formula (<italic>P</italic> = .001)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Rodrigues et al<sup><xref ref-type="bibr" rid="bibr9-1941406412439232">9</xref></sup> (2007)</td>
<td colspan="1" rowspan="1">To assess if polymeric formula was associated with an increased rate of adherence when compared with elemental formula</td>
<td colspan="1" rowspan="1">98 Children; 53 receiving elemental formula and 45 receiving polymeric formula</td>
<td colspan="1" rowspan="1">Retrospective study with medical record review</td>
<td colspan="1" rowspan="1">Adherence levels were relatively equal (<italic>P</italic> = .84); lower rates of NG tube administration with polymeric formula versus elemental formula (<italic>P</italic> = .02)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Rubio et al<sup><xref ref-type="bibr" rid="bibr19-1941406412439232">19</xref></sup> (2011)</td>
<td colspan="1" rowspan="1">To compare the efficacy of fractionated oral versus continuous enteral feeding on induction of remission in pediatric CD</td>
<td colspan="1" rowspan="1">106 Children (age range 7.5-14.7); 45 received EEN via the oral route; 61 received EEN via continuous enteral feeding for a period of 8 weeks</td>
<td colspan="1" rowspan="1">Retrospective study with medical record review</td>
<td colspan="1" rowspan="1">No significant differences in rates of remission between the 2 groups (<italic>P</italic> = .157); similar compliance rates observed (90% vs 87%)</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1">Maintenance of remission</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Takagi et al<sup><xref ref-type="bibr" rid="bibr20-1941406412439232">20</xref></sup> (2006)</td>
<td colspan="1" rowspan="1">To evaluate the efficacy of supplemental enteral nutrition as half the daily caloric intake during remission as compared with a normal diet</td>
<td colspan="1" rowspan="1">51 Patients (mean age of 30.8); 26 with half their caloric intake coming from enteral formula and 25 with a normal diet</td>
<td colspan="1" rowspan="1">RCT</td>
<td colspan="1" rowspan="1">Relapse rate was lower in those who continued using the enteral formula for half of daily caloric intake than those on a normal diet (no statistical values were reported)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Wilschanski et al<sup><xref ref-type="bibr" rid="bibr21-1941406412439232">21</xref></sup> (1996)</td>
<td colspan="1" rowspan="1">To evaluate if continuation of nocturnal enteral nutrition as supplementation to a normal diet increased the length of remission in pediatric CD</td>
<td colspan="1" rowspan="1">65 Children (age range 7-17 years) with active CD, treated with EEN for 4 weeks; 28 of those who achieved remission continued nocturnal supplementation in addition to normal diet</td>
<td colspan="1" rowspan="1">Medical record review</td>
<td colspan="1" rowspan="1">Relapse rates at 6 and 12 months were lower in those receiving nocturnal supplementation (<italic>P</italic> &lt; .02); improvement in linear growth was seen in those receiving nocturnal supplementation when used prior to puberty versus those who did not (<italic>P</italic> = .057)</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1">Long-term outcomes of enteral nutrition</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Knight et al<sup><xref ref-type="bibr" rid="bibr22-1941406412439232">22</xref></sup> (2005)</td>
<td colspan="1" rowspan="1">To show the short- and long-term effects of enteral nutrition as primary therapy in pediatric CD</td>
<td colspan="1" rowspan="1">79 Patients (age range 6.6-15.8 years); 44 chose enteral nutrition, and 35 chose steroid therapy</td>
<td colspan="1" rowspan="1">Nonrandomized trial; patients were given the choice of enteral nutrition or steroid therapy. Long-term follow-up ranged from 1 to 7 years</td>
<td colspan="1" rowspan="1">In all, 47% of patients avoided steroid use for 1 to 7 years; steroid use was postponed for a median of 68 weeks for those who required steroids; 38% remained in remission for 1 to 7 years (no statistical values reported)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Berni Canani et al<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> (2006)</td>
<td colspan="1" rowspan="1">To evaluate the efficacy of different enteral formulas (elemental, semielemental, and polymeric) and corticosteroids in their achievement of maintenance of disease remission</td>
<td colspan="1" rowspan="1">47 Patients (age range 7-17 years); 37 received 8 weeks of nutritional therapy, and 10 received corticosteroids</td>
<td colspan="1" rowspan="1">Retrospective study with medical record review</td>
<td colspan="1" rowspan="1">Similar remission rates; 86.5% using nutritional therapy achieved remission versus 90% using corticosteroids (no statistical values reported); those on nutritional therapy showed greater mucosal healing and durations of remission (<italic>P</italic> &lt; .001); duration of remission was longer in those who achieved remission via nutritional therapy (no statistical values reported)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Yamamoto et al<sup><xref ref-type="bibr" rid="bibr23-1941406412439232">23</xref></sup> (2007)</td>
<td colspan="1" rowspan="1">To evaluate the impact of enteral nutrition of clinical and endoscopic disease recurrence following resection</td>
<td colspan="1" rowspan="1">40 Patients (mean age 32 years) who required resection for ileal or ileocolonic CD; 20 received nocturnal enteral nutrition; 20 had a normal diet and no food restrictions</td>
<td colspan="1" rowspan="1">Prospective, nonrandomized, parallel, controlled study</td>
<td colspan="1" rowspan="1">Enteral nutrition reduced clinical and endoscopic disease recurrence at 1 year follow-up (clinical recurrence rate of enteral nutrition versus nonenteral nutrition <italic>P</italic> = .027)</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1">Alternative nutritional supplements</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Akobeng et al<sup><xref ref-type="bibr" rid="bibr24-1941406412439232">24</xref></sup> (2000)</td>
<td colspan="1" rowspan="1">To evaluate the efficacy of glutamine-enriched formula in the treatment of active CD</td>
<td colspan="1" rowspan="1">18 Children (age range 6.7-15.7 years); 9 received glutamine-enriched polymeric formula, and 9 received standard low-glutamine polymeric formula</td>
<td colspan="1" rowspan="1">RCT</td>
<td colspan="1" rowspan="1">Glutamine-enriched polymeric formula has no advantages over standard formula and was less effective in decreasing disease activity; there was no significant difference between remission rates in experimental and control groups (<italic>P</italic> = .5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bousvaros et al<sup><xref ref-type="bibr" rid="bibr25-1941406412439232">25</xref></sup> (2005)</td>
<td colspan="1" rowspan="1">To evaluate the role of LGG in the maintenance of pediatric CD</td>
<td colspan="1" rowspan="1">75 Patients (age range 5-21 years); 39 received LGG, and 36 received placebo</td>
<td colspan="1" rowspan="1">Double-blinded RCT</td>
<td colspan="1" rowspan="1">LGG’s role in the maintenance of remission is not supported; relapse rates were similar between both the control and experimental groups (<italic>P</italic> = .18)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Feagan et al<sup><xref ref-type="bibr" rid="bibr26-1941406412439232">26</xref></sup> (2008)</td>
<td colspan="1" rowspan="1">To evaluate the effect of high-dose omega-3 free fatty acids on the maintenance of CD remission</td>
<td colspan="1" rowspan="1">EPIC 1: 383 adult patients; 183 receiving omega-3 and 180 receiving placeboEPIC 2: 375 adult patients; 187 receiving omega-3 and 188 receiving placebo</td>
<td colspan="1" rowspan="1">2 Double-blind, placebo-controlled RCTs</td>
<td colspan="1" rowspan="1">No significant differences were shown in time to relapse or disease activity during 1 year of follow-up in either trial (EPIC 1, <italic>P</italic> = .30; EPIC 2, <italic>P</italic> = .48)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1941406412439232">
<p>Abbreviations: CD, Crohn’s disease; EEN, exclusive enteral nutrition; RCT, randomized controlled trial; NG, nasogastric; LGG, <italic>Lactobacillus</italic> GG.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Malnourished patients are at greater risk of infections, including sepsis and pneumonia. For patients who need surgery, the postoperative risks are higher with active CD.<sup><xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref></sup></p>
</sec>
</sec>
<sec id="section5-1941406412439232">
<title>Nutritional Management</title>
<p>The majority of children with CD present with some form of impaired nutritional status; therefore, nutritional management must play an integral part in the treatment of CD.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> Management of CD should be geared toward the induction of remission with the least number of side effects, thereby enabling improved growth and development.<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> The immediate goals of nutritional management are to induce and maintain remission to ultimately improve overall growth, development, and nutritional status. Exclusive enteral nutrition (EEN) is one option for the induction of remission in CD. Outside the United States, EEN therapy, lasting 6 to 12 weeks, is a popular method for inducing remission. However, in the United States, there are different recommendations regarding the nutritional management of pediatric CD. These are summarized in <xref ref-type="table" rid="table4-1941406412439232">Table 4</xref>.</p>
<table-wrap id="table4-1941406412439232" position="float">
<label>Table 4.</label>
<caption>
<p>Formal and Informal Nutritional Recommendations Regarding Enteral Nutrition in Management of CD</p>
</caption>
<graphic alt-version="no" alternate-form-of="table4-1941406412439232" position="float" xlink:href="10.1177_1941406412439232-table4.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<tbody>
<tr>
<td colspan="1" rowspan="1">American Dietetic Association<sup><xref ref-type="bibr" rid="bibr27-1941406412439232">27</xref></sup></td>
<td colspan="1" rowspan="1">Eat small meals every 3-4 hours<break/>When symptomatic, use low-fiber food<break/>Drink adequate fluids<break/>Eat foods with probiotic and prebiotic added<break/>Take a daily multivitamin<break/>When asymptomatic, introduce 1 new food</td>
</tr>
<tr>
<td colspan="1" rowspan="1">World Gastroenterology Organization Practice Guidelines<sup><xref ref-type="bibr" rid="bibr28-1941406412439232">28</xref></sup></td>
<td colspan="1" rowspan="1">Diet is a consideration and a liquid diet, predigested formula can reduce inflammation in children with CD<break/>Vitamin and mineral supplementation should be used during malnutrition or decreased oral intake<break/>Probiotics have not been shown to decrease symptoms of CD<break/>There are limited data to show that oligosaccharides, disaccharides, monosaccharides, and polyols can reduce symptoms of IBD</td>
</tr>
<tr>
<td colspan="1" rowspan="1">The American Society for Parenteral &amp; Enteral Nutrition<sup><xref ref-type="bibr" rid="bibr29-1941406412439232">29</xref></sup></td>
<td colspan="1" rowspan="1">Enteral nutrition should be used with pediatric CD patients with growth reduction<break/>Enteral therapy should be used to maintain nutrition status in times of decreased oral intake</td>
</tr>
<tr>
<td colspan="1" rowspan="1">The European Society for Clinical Nutrition and Metabolism Clinical Practice Guidelines<sup><xref ref-type="bibr" rid="bibr30-1941406412439232">30</xref></sup></td>
<td colspan="1" rowspan="1">To treat undernutrition, poor growth, and maintenance of remission, enteral nutrition is recommended<break/>Whole protein formulas are preferredInsufficient data to recommend glutamine, n-3fatty acids or other pharmaconutrients<break/>B12 and folate should be measured annually</td>
</tr>
<tr>
<td colspan="1" rowspan="1">The Japanese Society for Pediatric Gastroenterology, Hepatology, and Nutrition<sup><xref ref-type="bibr" rid="bibr31-1941406412439232">31</xref></sup></td>
<td colspan="1" rowspan="1">Elemental formula and oral mesalazine should be used at the onset and during remission of the disease</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Crohn’s and Colitis Foundation of America<sup><xref ref-type="bibr" rid="bibr24-1941406412439232">24</xref></sup></td>
<td colspan="1" rowspan="1">Special liquid diet may be helpful<break/>Restrict high-fiber food<break/>Eat smaller meals at frequent intervals<break/>Limit milk if lactose intolerant</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1941406412439232">
<p>Abbreviations: CD, Crohn’s disease; IBD, irritable bowel disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section6-1941406412439232">
<title>Induction of Remission</title>
<p>Unlike standard corticosteroid therapy, EEN therapy can benefit both growth and development and therefore should be considered as an alternative.<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup> Not only has EEN therapy shown to be effective in the induction of remission, but it also has higher remission rates at follow-up than corticosteroid therapy despite use of the same maintenance regimen.<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> <xref ref-type="table" rid="table3-1941406412439232">Table 3</xref> summarizes the studies on the induction of remission. The major limitations in these studies are the small sample sizes and insufficient number of randomized control trials.</p>
</sec>
<sec id="section7-1941406412439232">
<title>Exclusive Enteral Nutrition</title>
<sec id="section8-1941406412439232">
<title>Overview</title>
<p>Enteral diets are classified into amino acid–based elemental feeds, oligo-based or polypeptide-based semielemental feeds, and polymeric or whole protein–based diets.<sup><xref ref-type="bibr" rid="bibr32-1941406412439232">32</xref></sup> Appendix A (online at can.sagepub .com) reviews the types of formulas, composition, and cost. The side effect profile of these diets are excellent, with the exception of the risk of refeeding syndrome. Although the exact mechanism involved in EEN is unknown, proposed mechanisms include bowel rest, which is thought to decrease intestinal metabolic activity; alteration of intestinal flora; immunological effects, including the alteration of direct anti-inflammatory effects; and nutritional enhancement, including the improvement of caloric intake and correction of nutrient deficiencies.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref>,<xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref>,<xref ref-type="bibr" rid="bibr33-1941406412439232">33</xref></sup> There are several goals of EEN as it relates to the induction of remission in CD, including the prevention or treatment of malnutrition, improvement in growth and development, and improvement in the quality of life.<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup></p>
<p>According to the European Society for Clinical Nutrition and Metabolism’s Guidelines on Enteral Nutrition (2006) and its guidelines on parenteral therapy (2009), EEN therapy should be considered first-line therapy in pediatric patients with CD.<sup><xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref>,<xref ref-type="bibr" rid="bibr30-1941406412439232">30</xref></sup> Western Europeans hold a stronger belief in the efficacy of EEN than their US counterparts. Among Western Europeans, 79% reported believing in EEN to induce remission in comparison to 46% of US respondents.<sup><xref ref-type="bibr" rid="bibr34-1941406412439232">34</xref></sup></p>
<p>The question then becomes whether EEN is necessary for the induction of remission or if partial enteral nutrition (PEN) as supplementation to a normal diet might have similar effects. Johnson et al<sup><xref ref-type="bibr" rid="bibr18-1941406412439232">18</xref></sup> compared the effects of EEN with PEN in the induction of remission. Results showed that EEN yielded a greater remission rate than PEN, and PEN did not positively affect intestinal inflammation. The authors therefore recommend the use of EEN in the induction of disease remission.</p>
<p>EEN has been shown to induce remission in 60% to 90% of children with CD,<sup><xref ref-type="bibr" rid="bibr40-1941406412439232">40</xref></sup> with length of remission and relapse rate comparable to standard corticosteroid treatment.<sup><xref ref-type="bibr" rid="bibr30-1941406412439232">30</xref></sup> Two meta-analyses reported no difference between steroid-induced remission and EEN-induced remission.<sup><xref ref-type="bibr" rid="bibr35-1941406412439232">35</xref>,<xref ref-type="bibr" rid="bibr36-1941406412439232">36</xref></sup> Day et al<sup><xref ref-type="bibr" rid="bibr37-1941406412439232">37</xref></sup> found that EEN is most effective in the induction of disease remission when used in children with newly diagnosed CD; EEN induced remission in 80% of newly diagnosed patients versus 58% of children with long-standing disease.</p>
</sec>
<sec id="section9-1941406412439232">
<title>Beginning EEN therapy</title>
<p>The induction of remission via EEN involves a slow increase of enteral formula intake over a period of 2 to 3 days to ensure tolerance and reduce diarrhea.<sup><xref ref-type="bibr" rid="bibr34-1941406412439232">34</xref></sup> Minor disturbances such as nausea and headache can occur, but the side effects decrease as adaptation to the diet occurs. EEN commences once tolerance is determined and continues for approximately 4 to 8 weeks. Elemental, semielemental, or polymeric formula may be used.<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup> Growing infants, children, and adolescents have a high energy need especially in situations of prior weight loss or infection. The caloric needs for infants range from 80 to 120 kcal/kg/d with a protein requirement of 2.0 to 25 g/kg/d.<sup><xref ref-type="bibr" rid="bibr38-1941406412439232">38</xref></sup> EEN can either be given orally or via a nasogastric (NG) tube, with oral administration being the preferred method. NG tube feedings may be used when a large volume of formula is required or when oral administration is not feasible. If a child is receiving enteral nutrition by NG tube, the infusion rates should start at 20 mL/h and increase up to 100 to 120 mL/h, depending on weight. The insertion of an NG tube can be a deterrent to the use of EEN, but studies have shown that children can be taught to swallow an NG tube at night and can receive up to 1000 kcal/night.<sup><xref ref-type="bibr" rid="bibr15-1941406412439232">15</xref></sup> Rubio et al<sup><xref ref-type="bibr" rid="bibr19-1941406412439232">19</xref></sup> conducted a study of 106 pediatric patients recently and compared fractionated oral therapy with continuous enteral feeding; they did not find any difference in induction of remission, with similar compliance rates between oral and NG feeding (90% and 87%). According to the European Guidelines, induction of a normal diet is not permitted during EEN therapy<sup><xref ref-type="bibr" rid="bibr30-1941406412439232">30</xref></sup> and is associated with a lower remission rate in a recent pediatric study.<sup><xref ref-type="bibr" rid="bibr17-1941406412439232">17</xref></sup></p>
</sec>
<sec id="section10-1941406412439232">
<title>Polymeric formula</title>
<p>Polymeric formulas are more palatable than elemental formulas and thus can be taken orally<sup><xref ref-type="bibr" rid="bibr33-1941406412439232">33</xref></sup> without significant difference in the induction of remission.<sup><xref ref-type="bibr" rid="bibr39-1941406412439232">39</xref></sup> Rodrigues et al<sup><xref ref-type="bibr" rid="bibr9-1941406412439232">9</xref></sup> found that although there was no increase in adherence to therapy, there was a decrease in the number of patients requiring NG administration of the formula. The authors also noted that both polymeric and elemental formulas are comparable in efficacy. Similarly, Day et al<sup><xref ref-type="bibr" rid="bibr37-1941406412439232">37</xref></sup> found that polymeric formula has greater oral tolerability when compared with elemental formula and can therefore be given without an NG tube. Ludvigsson et al<sup><xref ref-type="bibr" rid="bibr18-1941406412439232">18</xref></sup> found that a polymeric diet has better treatment outcomes than an elemental diet.</p>
</sec>
<sec id="section11-1941406412439232">
<title>Pros and cons</title>
<p>There are many benefits to the use of EEN for the induction of remission in the pediatric population. It is important to note that there are very few negative side effects related to this therapeutic option, and the child is able to avoid all corticosteroid-associated side effects, including impaired linear growth, decreased bone density, and cosmetic side effects.<sup><xref ref-type="bibr" rid="bibr37-1941406412439232">37</xref></sup> EEN yields a greater improvement in nutritional status, linear growth, and mucosal healing than corticosteroid therapy. Linear growth improvement is partly achieved through control of mucosal inflammation.<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> Finally, EEN use decreases the need for corticosteroids.<sup><xref ref-type="bibr" rid="bibr40-1941406412439232">40</xref></sup></p>
<p>Although there are many benefits to EEN use, there are some drawbacks to consider. Although compliance with therapy can be upward of 90% in pediatric patients,<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref>,<xref ref-type="bibr" rid="bibr19-1941406412439232">19</xref></sup> it is still one of the greatest potential problems associated with this therapeutic modality. Lack of formula palatability can decrease compliance. However, polymeric formula is more palatable than elemental formula, and commercially available flavorings can be added.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> Similarly, a large volume of formula is required for efficacy—an amount not all patients are capable of consuming. NG tube feeds are always an option because some formulas can be concentrated.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> The cost of the formula and lifestyle modifications may be a deterrent in the use of this therapy.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> Finally, food exclusion with a liquid diet is difficult to maintain and can affect compliance.<sup><xref ref-type="bibr" rid="bibr39-1941406412439232">39</xref></sup></p>
</sec>
</sec>
<sec id="section12-1941406412439232">
<title>Maintenance of Remission</title>
<p>Nutrition remains a top priority once remission is achieved. Enteral nutrition, when taken as an oral supplement with a normal diet, can play a role in the maintenance of disease remission.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> Supplemental enteral nutrition can help reduce the risk of relapse; provide continued improvement of nutritional status, growth, and development<sup><xref ref-type="bibr" rid="bibr41-1941406412439232">41</xref></sup>; facilitate catch-up growth; and help support weight gain. There is no significant difference in the maintenance of remission between elemental and polymeric formulas.<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup></p>
<p>There are various delivery methods of enteral nutrition, including overnight NG tube feeds, oral supplementation to a regular diet, or intermittent cycles alternating EEN with a normal diet.<sup><xref ref-type="bibr" rid="bibr42-1941406412439232">42</xref></sup> Nocturnal supplementation, specifically, allows for the child to maintain a normal diet throughout the day while continuing the benefits of additional calories and nutrients at night. This should be considered for those children who lack improvement in nutritional status despite concurrent treatment of the disease. With this method, the child is able to remove the NG tube prior to school.<sup><xref ref-type="bibr" rid="bibr43-1941406412439232">43</xref></sup> A recent systematic review of enteral nutrition for the maintenance of remission concluded that the level of evidence was not high because of a small sample size and lack of consistency between the studies. However, authors also concluded that supplemental enteral therapy can be helpful in maintaining remission.<sup><xref ref-type="bibr" rid="bibr44-1941406412439232">44</xref></sup> In a study of adult patients with CD, Takagi et al<sup><xref ref-type="bibr" rid="bibr20-1941406412439232">20</xref></sup> found that when patients continue to consume elemental formula for half of their daily calories, the relapse rate was lower than for those who did not. Wilschanski et al<sup><xref ref-type="bibr" rid="bibr21-1941406412439232">21</xref></sup> conducted a study in which 28 children with remission induced by EEN were maintained by a regular diet with overnight supplementation. Two recent reviews pointed to the use of EEN for induction of remission of CD with supplemental enteral therapy as part of maintenance therapy.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref>,<xref ref-type="bibr" rid="bibr45-1941406412439232">45</xref></sup></p>
<p>The use of enteral nutrition during maintenance can delay and decrease the need for corticosteroids.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> Drawbacks of enteral nutrition during maintenance of remission are also similar to those during induction of remission. These include palatability of the formula, ease of use of supplemental formula, and lifestyle changes involved when using nutritional therapy. Knight et al<sup><xref ref-type="bibr" rid="bibr22-1941406412439232">22</xref></sup> found that when given the option of using either corticosteroids or supplemental enteral feeds, only 55% of their patients elected to use the supplemental enteral feeds. Although they did not explore the reasons, it seems likely that the lifestyle changes are too great.</p>
<p>There are several different approaches to the reintroduction of a normal diet during remission, which ranges between 1 and 12 weeks.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup> The most common approach is a gradual reintroduction of a normal diet. One meal is added every 2 to 3 days with a simultaneous reduction in enteral formula volume. Similarly, other approaches involve the graduation from liquids to soft foods and then a normal diet or gradual reintroduction of low-fat, low-fiber foods initially before the introduction of a normal diet.<sup><xref ref-type="bibr" rid="bibr11-1941406412439232">11</xref></sup> Food intolerances are not uncommon, and it is suggested that after remission with EEN, a new food item should be introduced every few days.<sup><xref ref-type="bibr" rid="bibr15-1941406412439232">15</xref></sup> Common food intolerances include wheat, milk, vegetables, citrus fruit, tomatoes, and yeast.<sup><xref ref-type="bibr" rid="bibr15-1941406412439232">15</xref></sup> Other approaches include the immediate reintroduction of a normal diet with an immediate decrease in overnight formula feeds.<sup><xref ref-type="bibr" rid="bibr4-1941406412439232">4</xref></sup></p>
<p>Once food is reintroduced, the question then becomes what a child should eat when in remission. In general, diet during remission should be varied and include fruits, vegetables, meat, oil, fish, fiber, and dairy products. Milk should not be restricted unless the child is lactose intolerant. If this is the case, it is important to add other calcium-enriched products.<sup><xref ref-type="bibr" rid="bibr46-1941406412439232">46</xref></sup> The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition recommends a balanced diet that includes all nutrients, based on the Food Guide Pyramid for children with CD.<sup><xref ref-type="bibr" rid="bibr47-1941406412439232">47</xref></sup> Dietary supplementation should also be considered during remission, including calcium, vitamin D, and iron supplements.<sup><xref ref-type="bibr" rid="bibr46-1941406412439232">46</xref></sup> Iron supplementation can improve the quality of life.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> In addition, if the patient is receiving sulfasalazine as part of his or her medical therapy, vitamin B12 supplementation will be needed.<sup><xref ref-type="bibr" rid="bibr15-1941406412439232">15</xref></sup></p>
</sec>
<sec id="section13-1941406412439232">
<title>Long-term Outcomes of Enteral Nutrition</title>
<p>After achieving an initial remission of CD, the question then becomes what impact enteral nutrition has on the length of remission. Berni Canani et al<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> found that nutritional therapy has a greater healing effect on the intestinal mucosa when compared with corticosteroid therapy. This effect on the mucosa was associated with a decrease in relapse rate within 1 year, indicating that the degree of mucosa healing is important in long-term remission rates.</p>
<p>Similarly, Knight et al<sup><xref ref-type="bibr" rid="bibr22-1941406412439232">22</xref></sup> conducted a study evaluating the long-term effects of enteral nutrition use. The authors found that the vast majority of those who received enteral nutrition achieved remission, with 38% remaining in remission from 1 to 7 years. Those who chose to continue with steroid therapy following relapse avoided steroids for a median of 68 weeks, which was related to enteral formula use.</p>
<p>The use of enteral nutrition can also have an impact on disease recurrence. Typically, disease recurrence is high following bowel resection.<sup><xref ref-type="bibr" rid="bibr23-1941406412439232">23</xref></sup> Yamamoto et al<sup><xref ref-type="bibr" rid="bibr23-1941406412439232">23</xref></sup> conducted a study evaluating the effects of long-term enteral nutrition on the rates of clinical and endoscopic recurrence of the disease after resection in adult patients. Results indicated that long-term enteral nutrition decreased the rate of disease recurrence both clinically and endoscopically, with only 1 patient experiencing disease recurrence.</p>
</sec>
<sec id="section14-1941406412439232">
<title>Alternative Nutritional Supplements</title>
<sec id="section15-1941406412439232">
<title>Omega-3 free fatty acids</title>
<p>Omega-3 free fatty acids are substances that can be found in marine life and can provide various health benefits. One possible important benefit is a decrease in the arachidonic acid found in inflammatory cells.<sup><xref ref-type="bibr" rid="bibr48-1941406412439232">48</xref></sup> Feagan et al<sup><xref ref-type="bibr" rid="bibr26-1941406412439232">26</xref></sup> conducted 2 trials evaluating the effects of omega-3 free fatty acids on the maintenance of CD in the adult population. The results indicated that there was no difference between placebo and omega-3 free fatty acid on the length of remission. Turner et al<sup><xref ref-type="bibr" rid="bibr48-1941406412439232">48</xref></sup> also came to a similar conclusion, stating that data do not support the use of omega-3 free fatty acids in the maintenance of CD.</p>
</sec>
<sec id="section16-1941406412439232">
<title>Probiotics</title>
<p>Probiotics are oral nutritional supplements containing microorganisms that can offer health benefits by altering host microflora.<sup><xref ref-type="bibr" rid="bibr49-1941406412439232">49</xref></sup> Mechanisms of action include anti-inflammatory properties related to the production of anti-inflammatory cytokines and the suppression of proinflammatory cytokines, enhancement of the gut barrier, and, importantly, the regulation of mucosal immune response.<sup><xref ref-type="bibr" rid="bibr50-1941406412439232">50</xref></sup> Guandalini<sup><xref ref-type="bibr" rid="bibr50-1941406412439232">50</xref></sup> does not recommend the use of probiotics because of the lack of positive evidence. Similarly, Bousvaros et al<sup><xref ref-type="bibr" rid="bibr25-1941406412439232">25</xref></sup> evaluated the effects of <italic>Lactobacillus GG</italic> on the maintenance of pediatric CD. Results indicated that both <italic>Lactobacillus GG</italic> and placebo had the same effect on disease relapse rate. Therefore, the authors concluded that there is no role for probiotics as supplemental therapy in the maintenance of pediatric CD. Finally, the American Academy of Pediatrics also does not recommend the use of probiotics in children because of the lack of efficacy in the maintenance of CD.<sup><xref ref-type="bibr" rid="bibr49-1941406412439232">49</xref></sup></p>
</sec>
<sec id="section17-1941406412439232">
<title>Glutamine</title>
<p>Glutamine, a nonessential amino acid, may be protective against intestinal mucosal atrophy and therefore play a role in the maintenance of CD.<sup><xref ref-type="bibr" rid="bibr12-1941406412439232">12</xref></sup> Animal studies on the effects of glutamine in inflammatory bowel disease have shown positive results, including decreased weight loss, less severe mucosal damage, and reduced disease activity. Akobeng et al<sup><xref ref-type="bibr" rid="bibr24-1941406412439232">24</xref></sup> conducted a study evaluating the efficacy of using glutamine-enriched formula as a treatment for active CD. Results indicated that a glutamine-enriched polymeric formula held no advantages over a standard low-glutamine formula. The authors, therefore, do not recommend the use of glutamine-enriched formula in the treatment of CD. <xref ref-type="table" rid="table3-1941406412439232">Table 3</xref> summarizes studies evaluating different alternative nutritional supplements.</p>
</sec>
</sec>
</sec>
<sec id="section18-1941406412439232">
<title>Summary</title>
<p>Like JR, children with CD experience growth and development delays, along with many other nutritional deficits. Treatment and management of the disease not only has to target the associated symptoms but also the nutritional deficits and growth impairment. Nutritional therapy is optimal for a patient like JR. The goal of nutritional therapy is to help improve nutritional status, promote growth and development, and induce and maintain disease remission. EEN has been shown to be as effective as corticosteroids in the induction of remission of pediatric CD, without the side effect profile of standard steroid therapy. Enteral nutrition has also been shown to be useful in supplementation with an oral diet. No specific dietary restrictions are recommended during the maintenance of remission. Supplementation with omega-3 free fatty acids, probiotics, or glutamine has not been proven to be useful in the maintenance of remission of pediatric CD.</p>
</sec>
<sec id="section19-1941406412439232">
<title>Role of the Health Care Professional</title>
<sec id="section20-1941406412439232">
<title>Clinical Practice</title>
<p>The gastroenterologist, primary care provider, dietitian, registered nurse, nurse practitioner, and social worker are part of the multidisciplinary team in the management of the child with CD.<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup> Nutritional monitoring is fundamental in the management of this population. Periodic assessment of growth and nutritional status is imperative and should begin at diagnosis and continue every 6 months.<sup><xref ref-type="bibr" rid="bibr7-1941406412439232">7</xref></sup> Box 1 reviews the components of nutritional assessment. If dietary intake of micronutrients is inadequate, it is appropriate to suggest nutritional supplementation with multivitamins, calcium supplements, and vitamin D supplements.<sup><xref ref-type="bibr" rid="bibr40-1941406412439232">40</xref></sup> Measuring B12 levels and folate levels should be done annually in patients with ileal CD.<sup><xref ref-type="bibr" rid="bibr8-1941406412439232">8</xref></sup> Because food intolerances are individual to each patient, patients should be encouraged to keep a food diary and have it reviewed at each visit to assess any possible intolerance to foods. If caloric intake is deficient, consideration of supplemental enteral nutrition is appropriate. Physical activity should be recommended and encouraged, with no limitation as to activity type. Bed rest should also be discouraged.<sup><xref ref-type="bibr" rid="bibr40-1941406412439232">40</xref></sup></p>
<boxed-text id="boxed-text1-1941406412439232" position="float">
<sec id="section21-1941406412439232">
<title>Box 1.</title>
<p>Assessment of Nutritional Status in Patient With Crohn’s Disease.</p>
<list id="list6-1941406412439232" list-type="order">
<list-item><p>Assessment of growth: height for age, weight for age, BMI<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
<list-item><p>Assessment of Tanner stages<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
<list-item><p>Assessment of caloric intake<sup><xref ref-type="bibr" rid="bibr10-1941406412439232">10</xref></sup></p></list-item>
<list-item><p>Assessment of nutrient intake<sup><xref ref-type="bibr" rid="bibr40-1941406412439232">40</xref></sup>
<list id="list7-1941406412439232" list-type="bullet">
<list-item><p>Protein</p></list-item>
<list-item><p>Fat</p></list-item>
<list-item><p>Carbohydrates</p></list-item>
<list-item><p>Vitamin D</p></list-item>
<list-item><p>Calcium</p></list-item>
<list-item><p>Iron</p></list-item>
<list-item><p>Vitamin B12</p></list-item>
<list-item><p>Folate</p></list-item>
<list-item><p>Zinc</p></list-item>
</list></p></list-item></list>
</sec>
</boxed-text>
<p>Patient and family education, collaboration with all team members, and motivation are essential in the nutritional therapy of pediatric CD. Both the patient and family have to be prepared and willing to implement the lifestyle changes necessary for such management. Working as part of a multidisciplinary team can improve education and understanding of this treatment option. The team members help facilitate the motivation necessary to comply with and complete prescribed therapies.<sup><xref ref-type="bibr" rid="bibr16-1941406412439232">16</xref></sup> It is important to monitor the patient and family’s ability and willingness to comply with a plan of care and alter the plan if noncompliance becomes problem.<sup><xref ref-type="bibr" rid="bibr40-1941406412439232">40</xref></sup> The best way to ensure compliance is to discuss treatment options and use shared decision making to develop an individualized plan.</p>
<p>It is vital to discuss with both the child and family the nutritional effects of CD on the child’s body, especially focusing on growth and pubertal development in adolescence. Impairments in these parameters can have a significant psychosocial impact on the child. Concerns about body image are ranked high among the adolescent population with CD, especially when differences between peers become increasingly obvious.<sup><xref ref-type="bibr" rid="bibr51-1941406412439232">51</xref></sup></p>
</sec>
<sec id="section22-1941406412439232">
<title>Support Groups</title>
<p>The lives of both the child and family are altered when the child is diagnosed with CD, and as a result, support groups can be beneficial to this population. Both the patient and family should be put in contact with others who have completed the same therapy because it can benefit children to hear positive outcomes.<sup><xref ref-type="bibr" rid="bibr37-1941406412439232">37</xref></sup> Patients and families can be directed to the Crohn’s &amp; Colitis Foundation of America, which has chapters available by state, some of which have special programs for children and adolescents. These chapters provide support resources, including community outreach, support groups, and various educational materials for patients, families, and health care providers.<sup><xref ref-type="bibr" rid="bibr52-1941406412439232">52</xref></sup></p>
</sec>
<sec id="section23-1941406412439232">
<title>Education</title>
<p>Nutrition and nutritional management of this patient population is crucial. Members of the health care team need to be educated regarding general nutrition, the common nutritional deficiencies seen in CD, the importance of micronutrient dietary supplementation, nutritional therapy during both active and remissive states of CD, and the importance of compliance with treatment. It is essential for the team members to work with the dietitian and gastroenterologist to encourage the patient to maintain a balanced diet with adequate caloric and nutritional intake when not receiving EEN. It is also important to keep up to date on current research regarding the management of this population. Working with a trained, registered dietitian can help team members understand the disease process, treatment, and side effects of the alternative treatment options.</p>
</sec>
<sec id="section24-1941406412439232">
<title>Future Research</title>
<p>Nutritional management of the child with CD has come very far since its beginnings; however, there are still many aspects that need further research. There are few large, randomized controlled trials evaluating different nutritional therapies in the pediatric population. Rather, most studies include small patient populations and are not randomized. In addition, there needs to be additional studies on the mechanism of action in nutrition therapy.</p>
<p>Additional research is required to determine whether the partial use of enteral feeds can be effective in inducing remission. Further research is also necessary in the area of diet and dietary management of CD, specifically in the area of triggers or irritants. There appears to be no official consensus on the protocol of reintroducing a regular diet following EEN. It would be beneficial to develop a guideline for food reintroduction that is best for the patient. As mentioned, compliance with nutritional therapy, especially regarding the use of enteral formula, is problematic. Research should explore new ways to flavor the formula for palatability or concentrate it to decrease the volume of intake. It would also be beneficial to increase the amount of research evaluating the long-term benefits and outcomes of enteral nutrition and nutritional management in the pediatric population. Finally, additional research is needed in the area of alternative nutritional therapies and supplementation, including prebiotics and other complementary and alternative medicine modalities.■</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1941406412439232">
<label>1.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Pons</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Whitten</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Woodhead</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Leach</surname><given-names>ST</given-names></name>
<name name-style="western"><surname>Lemberg</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Dietary intakes of children with Crohn’s disease</article-title>. <source>Br J Nutr</source>. <year>2009</year>;<volume>102</volume>:<fpage>1052</fpage>-<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr2-1941406412439232">
<label>2.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Walsh</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mabee</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Trivedi</surname><given-names>K</given-names></name>
</person-group>. <article-title>Inflammatory bowel disease</article-title>. <source>Prim Care</source>. <year>2011</year>;<volume>38</volume>:<fpage>415</fpage>-<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr3-1941406412439232">
<label>3.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Szigethy</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Mclafferty</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Goyal</surname><given-names>A</given-names></name>
</person-group>. <article-title>Inflammatory bowel disease</article-title>. <source>Child Adolesc Psychiatr Clin N Am</source>. <year>2010</year>;<volume>19</volume>:<fpage>301</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr4-1941406412439232">
<label>4.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Otley</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Russell</surname><given-names>RK</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Nutritional therapy for the treatment of pediatric Crohn’s disease</article-title>. <source>Expert Rev Clin Immunol</source>. <year>2010</year>;<volume>6</volume>:<fpage>667</fpage>-<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr5-1941406412439232">
<label>5.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kugathasan</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Nebel</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Skelton</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts</article-title>. <source>J Pediatr</source>. <year>2007</year>;<volume>151</volume>:<fpage>523</fpage>-<lpage>527</lpage>.</citation>
</ref>
<ref id="bibr6-1941406412439232">
<label>6.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Akobeng</surname><given-names>AK</given-names></name>
</person-group>. <article-title>Crohn’s disease: current treatment options</article-title>. <source>Arch Dis Child</source>. <year>2008</year>;<volume>93</volume>:<fpage>787</fpage>-<lpage>792</lpage>.</citation>
</ref>
<ref id="bibr7-1941406412439232">
<label>7.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wiskin</surname><given-names>AE</given-names></name>
<name name-style="western"><surname>Wootton</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Beattie</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Nutritional issues in pediatric Crohn’s disease</article-title>. <source>Nutr Clin Pract</source>. <year>2007</year>;<volume>22</volume>:<fpage>214</fpage>-<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr8-1941406412439232">
<label>8.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Van Gossum</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Cabre</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Hebuterne</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN guidelines on parenteral nutrition: gastroenterology</article-title>. <source>Eur Soc Clin Nutr Metab</source>. <year>2009</year>;<volume>28</volume>:<fpage>415</fpage>-<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr9-1941406412439232">
<label>9.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rodrigues</surname><given-names>AF</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Davies</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Murphy</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn’s disease?</article-title> <source>Arch Dis Child</source>. <year>2007</year>;<volume>92</volume>:<fpage>767</fpage>-<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr10-1941406412439232">
<label>10.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heuschkel</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Salvestrini</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Beattie</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Hildebrand</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Walters</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Griffiths</surname><given-names>A</given-names></name>
</person-group>. <article-title>Guidelines for the management of growth failure in childhood inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2008</year>;<volume>14</volume>:<fpage>839</fpage>-<lpage>849</lpage>.</citation>
</ref>
<ref id="bibr11-1941406412439232">
<label>11.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Day</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Whitten</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>de Jong</surname><given-names>NSH</given-names></name>
</person-group>. <article-title>Nutrition and nutritional management of Crohn’s disease in children and adolescents</article-title>. <source>Curr Nutr Food Sci</source>. <year>2006</year>;<volume>2</volume>:<fpage>3</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr12-1941406412439232">
<label>12.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>El-Matary</surname><given-names>W</given-names></name>
</person-group>. <article-title>Enteral nutrition as a primary therapy of Crohn’s disease: the pediatric perspective</article-title>. <source>Nutr Clin Pract</source>. <year>2009</year>;<volume>24</volume>:<fpage>91</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr13-1941406412439232">
<label>13.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Levin</surname><given-names>AD</given-names></name>
<name name-style="western"><surname>Wadhera</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Leach</surname><given-names>ST</given-names></name>
<etal/>
</person-group>. <article-title>Vitamin D deficiency in children with inflammatory bowel disease</article-title>. <source>Dig Dis Sci</source>. <year>2011</year>;<volume>56</volume>:<fpage>830</fpage>-<lpage>836</lpage>.</citation>
</ref>
<ref id="bibr14-1941406412439232">
<label>14.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Siffledeen</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Fedorak</surname><given-names>RN</given-names></name>
<name name-style="western"><surname>Siminoski</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn’s disease</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2005</year>;<volume>3</volume>:<fpage>122</fpage>-<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr15-1941406412439232">
<label>15.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lochs</surname><given-names>H</given-names></name>
</person-group>. <article-title>Basics in clinical nutrition: nutritional support in inflammatory bowel disease</article-title>. <source>e-SPEN</source>. <year>2010</year>;<volume>5</volume>:<fpage>e100</fpage>-<lpage>e103</lpage>.</citation>
</ref>
<ref id="bibr16-1941406412439232">
<label>16.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berni Canani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Terrin</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Borrelli</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease</article-title>. <source>Dig Liver Dis</source>. <year>2006</year>;<volume>38</volume>:<fpage>381</fpage>-<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr17-1941406412439232">
<label>17.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Johnson</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Macdonald</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hill</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Murphy</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial</article-title>. <source>Gut</source>. <year>2006</year>;<volume>55</volume>:<fpage>356</fpage>-<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr18-1941406412439232">
<label>18.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ludvigsson</surname><given-names>JF</given-names></name>
<name name-style="western"><surname>Krantz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Bodin</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Stenhammar</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Lindquist</surname><given-names>B</given-names></name>
</person-group>. <article-title>Elemental versus polymeric enteral nutrition in paediatric Crohn’s disease: a multicentre randomized controlled trail</article-title>. <source>Acta Paediatr</source>. <year>2004</year>;<volume>93</volume>:<fpage>327</fpage>-<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr19-1941406412439232">
<label>19.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rubio</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Pigmeir</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Garnier-Lengline</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>The efficacy of exclusive nutrition therapy in paediatric Crohn’s disease, comparing fractionated oral vs. continuous enteral feeding</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2011</year>;<volume>33</volume>:<fpage>1332</fpage>-<lpage>1339</lpage>.</citation>
</ref>
<ref id="bibr20-1941406412439232">
<label>20.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Takagi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Utsunomiya</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Kuriyama</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Effectiveness of an “half elemental diet” as maintenance therapy for Crohn’s disease: a randomized-controlled trial</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2006</year>;<volume>24</volume>:<fpage>1333</fpage>-<lpage>1340</lpage>.</citation>
</ref>
<ref id="bibr21-1941406412439232">
<label>21.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wilschanski</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Sharman</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Pencharz</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Davis</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Corey</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Griffith</surname><given-names>A</given-names></name>
</person-group>. <article-title>Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease</article-title>. <source>Gut</source>. <year>1996</year>;<volume>38</volume>:<fpage>543</fpage>-<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr22-1941406412439232">
<label>22.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Knight</surname><given-names>C</given-names></name>
<name name-style="western"><surname>El-Matary</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Spray</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Sandhu</surname><given-names>BK</given-names></name>
</person-group>. <article-title>Long-term outcome of nutritional therapy in paediatric Crohn’s disease</article-title>. <source>Clin Nutr</source>. <year>2005</year>;<volume>24</volume>:<fpage>775</fpage>-<lpage>779</lpage>.</citation>
</ref>
<ref id="bibr23-1941406412439232">
<label>23.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Nakahigashi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Umegae</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kitagawa</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name>
</person-group>. <article-title>Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2007</year>;<volume>25</volume>:<fpage>67</fpage>-<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr24-1941406412439232">
<label>24.</label>
<citation citation-type="web" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Akobeng</surname><given-names>AK</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Stanton</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Elbadri</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2000</year>;<volume>30</volume>:<fpage>78</fpage>-<lpage>84</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="http://journals.lww.com/jpgn/Fulltext/2000/01000/Double_Blind_Randomized_Controlled_Trial_of.22.aspx" xlink:type="simple">http://journals.lww.com/jpgn/Fulltext/2000/01000/Double_Blind_Randomized_Controlled_Trial_of.22.aspx</ext-link></comment>. <access-date>Accessed February 3, 2012</access-date>.</citation>
</ref>
<ref id="bibr25-1941406412439232">
<label>25.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bousvaros</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Guandalini</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Baldassano</surname><given-names>RN</given-names></name>
<etal/>
</person-group>. <article-title>A randomized, double-blind trial of <italic>Lactobacillus GG</italic> versus placebo in addition to standard maintenance therapy for children with Crohn’s disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2005</year>;<volume>11</volume>:<fpage>833</fpage>-<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr26-1941406412439232">
<label>26.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Feagan</surname><given-names>BG</given-names></name>
<name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></name>
<name name-style="western"><surname>Mittmann</surname><given-names>U</given-names></name>
<etal/>
</person-group>. <article-title>Omega-3 free fatty acids for the maintenance of remission in Crohn’s disease: the EPIC Randomized Controlled Trials</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>299</volume>:<fpage>1690</fpage>-<lpage>1697</lpage>.</citation>
</ref>
<ref id="bibr27-1941406412439232">
<label>27.</label>
<citation citation-type="web" xlink:type="simple">
<collab xlink:type="simple">Academy of Nutrition and Dietetics</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.eatright.org" xlink:type="simple">www.eatright.org</ext-link>. <access-date>Accessed December 20, 2011</access-date>.</citation>
</ref>
<ref id="bibr28-1941406412439232">
<label>28.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bernstein</surname><given-names>CN</given-names></name>
<name name-style="western"><surname>Fried</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Krabshuis</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. <article-title>World Gastroenterology Organization Practice guidelines for diagnosis and management of IBD in 2010</article-title>. <source>Inflamm Bowel Dis</source>. <year>2010</year>;<volume>16</volume>:<fpage>112</fpage>-<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr29-1941406412439232">
<label>29.</label>
<citation citation-type="journal" xlink:type="simple">
<collab xlink:type="simple">ASPEN Board of Directors and the Clinical Guidelines Task Force</collab>. <article-title>Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, 2009</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>:<fpage>255</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr30-1941406412439232">
<label>30.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lochs</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Dejong</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Hammarqvist</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN guidelines on enteral nutrition: gastroenterology</article-title>. <source>Clin Nutr</source>. <year>2006</year>;<volume>25</volume>:<fpage>260</fpage>-<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr31-1941406412439232">
<label>31.</label>
<citation citation-type="journal" xlink:type="simple">
<collab xlink:type="simple">Working Group of Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition</collab>; <person-group person-group-type="author">
<name name-style="western"><surname>Konno</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kobabayashi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Tomamasa</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Guidelines for the treatment of Crohn’s disease patient in remission</article-title>. <source>Pediatr Int</source>. <year>2006</year>;<volume>22</volume>:<fpage>855</fpage>-<lpage>859</lpage>.</citation>
</ref>
<ref id="bibr32-1941406412439232">
<label>32.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tighe</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Cummings</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Afzal</surname><given-names>NA</given-names></name>
</person-group>. <article-title>Nutrition and inflammatory bowel disease: primary or adjuvant therapy</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2011</year>;<volume>14</volume>:<fpage>491</fpage>-<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr33-1941406412439232">
<label>33.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Makola</surname><given-names>D</given-names></name>
</person-group>. <article-title>Elemental and semi-elemental formulas: are they superior to polymeric formulas?</article-title> <source>Pract Gastroenterol</source>. <year>2005</year>;<volume>34</volume>:<fpage>59</fpage>-<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr34-1941406412439232">
<label>34.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Scholz</surname><given-names>D</given-names></name>
</person-group>. <article-title>The role of nutrition in etiology of inflammatory bowel disease</article-title>. <source>Curr Probl Pediatr Adolesc Health Care</source>. <year>2011</year>;<volume>41</volume>:<fpage>248</fpage>-<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr35-1941406412439232">
<label>35.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Heuschkel</surname><given-names>RB</given-names></name>
<name name-style="western"><surname>Menache</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Megerian</surname><given-names>JT</given-names></name>
<name name-style="western"><surname>Baird</surname><given-names>AE</given-names></name>
</person-group>. <article-title>Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2000</year>;<volume>31</volume>:<fpage>8</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr36-1941406412439232">
<label>36.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dziechciarz</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Horvath</surname></name>
<name name-style="western"><surname>Chamir</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Szajewska</surname><given-names>H</given-names></name>
</person-group>. <article-title>Meta-analysis: enteral nutrition in active Crohn’s disease in children</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2007</year>;<volume>26</volume>:<fpage>795</fpage>-<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr37-1941406412439232">
<label>37.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Day</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Whitten</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Lemberg</surname><given-names>DA</given-names></name>
<etal/>
</person-group>. <article-title>Exclusive enteral feeding as primary therapy for Crohn‘s disease in Australian children and adolescents: a feasible and effective approach</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2006</year>; <volume>21</volume>(<issue>10</issue>):<fpage>1609</fpage>-<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr38-1941406412439232">
<label>38.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Nelms</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Sucher</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Long</surname><given-names>S</given-names></name>
</person-group>. <source>Nutrition Therapy and Pathophysiology</source>. <publisher-loc>Belmont, CA</publisher-loc>: <publisher-name>Thomson Wadsworth</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr39-1941406412439232">
<label>39.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rajendran</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name>
</person-group>. <article-title>Role of diet in the management of inflammatory bowel disease</article-title>. <source>World J Gastroenterol</source>. <year>2010</year>;<volume>16</volume>:<fpage>1442</fpage>-<lpage>1448</lpage>.</citation>
</ref>
<ref id="bibr40-1941406412439232">
<label>40.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rufo</surname><given-names>PA</given-names></name>
<name name-style="western"><surname>Bousvaros</surname><given-names>A</given-names></name>
</person-group>. <article-title>Current therapy of inflammatory bowel disease in children</article-title>. <source>Paediatr Drugs</source>. <year>2006</year>;<volume>8</volume>:<fpage>279</fpage>-<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr41-1941406412439232">
<label>41.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sandhu</surname><given-names>BK</given-names></name>
<name name-style="western"><surname>Fell</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Beattie</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. <article-title>Guidelines for the management of inflammatory bowel disease in children in the United Kingdom</article-title> [<comment>published online ahead of print January 13, 2010</comment>]. <source>J Pediatr Gastroenterol Nutr</source>. doi:10.1097/MPG.0b013e3181c92c53<pub-id pub-id-type="doi">10.1097/MPG.0b013e3181c92c53</pub-id>.</citation>
</ref>
<ref id="bibr42-1941406412439232">
<label>42.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>El-Matary</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Zachos</surname><given-names>M</given-names></name>
</person-group>. <article-title>Nutritional therapy</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Mamula</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Markowitz</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Baldassano</surname><given-names>R</given-names></name>
</person-group>, eds. <source>Pediatric Inflammatory Bowel Disease</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>; <volume>2008</volume>:<fpage>337</fpage>-<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr43-1941406412439232">
<label>43.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kappelman</surname><given-names>MD</given-names></name>
<name name-style="western"><surname>Bousvaros</surname><given-names>A</given-names></name>
</person-group>. <article-title>Nutritional concerns in pediatric inflammatory bowel disease patients</article-title>. <source>Mol Nutr Food Res</source>. <year>2008</year>;<volume>52</volume>:<fpage>867</fpage>-<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr44-1941406412439232">
<label>44.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Nakahigashi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Umegae</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name>
</person-group>. <article-title>Enteral nutrition for the maintenance of remission in Crohn’s disease: a systematic review</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2010</year>;<volume>22</volume>:<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr45-1941406412439232">
<label>45.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wilson</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>AG</given-names></name>
<name name-style="western"><surname>Croft</surname><given-names>NM</given-names></name>
<name name-style="western"><surname>Newby</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Akobeng</surname><given-names>AK</given-names></name>
<name name-style="western"><surname>Sawczendo</surname><given-names>A</given-names></name>
</person-group>. <article-title>Systemic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2010</year>;<volume>50</volume>:<fpage>S14</fpage>-<lpage>S34</lpage>.</citation>
</ref>
<ref id="bibr46-1941406412439232">
<label>46.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lucendo</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>De Rezende</surname><given-names>LC</given-names></name>
</person-group>. <article-title>Importance of nutrition in inflammatory bowel disease</article-title>. <source>World J Gastroenterol</source>. <year>2009</year>;<volume>15</volume>:<fpage>2081</fpage>-<lpage>2088</lpage>.</citation>
</ref>
<ref id="bibr47-1941406412439232">
<label>47.</label>
<citation citation-type="web" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kleinman</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Baldassano</surname><given-names>RN</given-names></name>
<name name-style="western"><surname>Caplan</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2004</year>;<volume>39</volume>:<fpage>15</fpage>-<lpage>27</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="http://journals.lww.com/jpgn/Fulltext/2004/07000/Nutrition_Support_for_Pediatric_Patients_With.5.aspx" xlink:type="simple">http://journals.lww.com/jpgn/Fulltext/2004/07000/Nutrition_Support_for_Pediatric_Patients_With.5.aspx</ext-link></comment>. <access-date>Accessed February 3, 2012</access-date>.</citation>
</ref>
<ref id="bibr48-1941406412439232">
<label>48.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Turner</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Zlotkin</surname><given-names>SH</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>PS</given-names></name>
<name name-style="western"><surname>Griffiths</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2009</year>;<volume>1</volume>:<fpage>CD006320</fpage>.</citation>
</ref>
<ref id="bibr49-1941406412439232">
<label>49.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Thomas</surname><given-names>DW</given-names></name>
<name name-style="western"><surname>Greer</surname><given-names>FR</given-names></name>
</person-group>; <collab xlink:type="simple">American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition</collab>. <article-title>Probiotics and prebiotics in pediatrics</article-title>. <source>Pediatrics</source>. <year>2010</year>;<volume>126</volume>:<fpage>1217</fpage>-<lpage>1231</lpage>.</citation>
</ref>
<ref id="bibr50-1941406412439232">
<label>50.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Guandalini</surname><given-names>S</given-names></name>
</person-group>. <article-title>Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease</article-title>. <source>Expert Rev Clin Immunol</source>. <year>2010</year>;<volume>6</volume>:<fpage>47</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr51-1941406412439232">
<label>51.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Walters</surname><given-names>TD</given-names></name>
<name name-style="western"><surname>Griffiths</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Growth impairment in pediatric inflammatory bowel disease</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Mamula</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Markowitz</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Baldassano</surname><given-names>R</given-names></name>
</person-group> eds. <source>Pediatric Inflammatory Bowel Disease</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>; <volume>2008</volume>:<fpage>103</fpage>-<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr52-1941406412439232">
<label>52.</label>
<citation citation-type="web" xlink:type="simple">
<collab xlink:type="simple">Crohn’s &amp; Colitis Foundation of America</collab>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.ccfa.org" xlink:type="simple">http://www.ccfa.org</ext-link></comment> <access-date>Accessed May 31, 2011</access-date>.</citation>
</ref>
</ref-list>
</back>
</article>